Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries
Vaneck Pharmaceutical ETF
(NQ:
PPH
)
96.23
+0.04 (+0.04%)
Official Closing Price
Updated: 4:15 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaneck Pharmaceutical ETF
Ozempic Maker Novo Nordisk Closes In On Lego As Denmark's Most Valuable Brand: Report
June 12, 2024
Novo Nordisk is challenging Lego A/S for the title of Denmark's most valuable brand, with its brand value surging 59% to $5.1 billion. This growth is fueled by the global popularity of its weight-loss...
Via
Benzinga
Just Say No to Drugs: 3 Pharma Stocks to Avoid
May 08, 2024
Discover which pharma stocks to avoid in 2023 as we delve into market trends, financial struggles, and the impact on investor portfolios.
Via
InvestorPlace
A Look At Pharma ETFs Post Q1 Earnings
May 07, 2024
Pharma ETFs have delivered mixed performances over the past month.
Via
Talk Markets
Topics
ETFs
ETFs To Buy As Eli Lilly Beats Q1 Earnings, Lifts Outlook
May 01, 2024
Eli Lilly and Company posted mixed first-quarter 2024 earnings, beating earnings estimates but lagging on revenues. Investors seeking to tap the opportune moment could bet on ETFs having the largest...
Via
Talk Markets
Topics
ETFs
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom
April 17, 2024
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment.
Via
InvestorPlace
Topics
ETFs
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage
March 08, 2024
Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management.
Via
Benzinga
Exposures
Product Safety
The Top 3 ETFs to Buy in March 2024
March 07, 2024
Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside.
Via
InvestorPlace
Topics
ETFs
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields
February 28, 2024
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year.
Via
Benzinga
A Look At Pharma ETFs After Q4 Earnings
February 12, 2024
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth.
Via
Talk Markets
Topics
ETFs
5 ETF Zones Scaling New Highs At The Start Of 2024
January 08, 2024
The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs.
Via
Talk Markets
Topics
ETFs
Government-granted Patent Monopolies Are Not The Free Market
December 29, 2023
Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -...
Via
Talk Markets
Topics
Intellectual Property
Exposures
Intellectual Property
Preparing For The Next Short-Term Rally Higher
August 12, 2023
The short-term downtrend appears set to continue. The market is taking the time it needs to consolidate near its short-term trend lows in order to prepare a base from which it can begin its next...
Via
Talk Markets
Pharma ETFs in Focus Post Q2 Earnings
August 11, 2023
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth.
Via
Talk Markets
Topics
ETFs
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023
July 21, 2023
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market.
Via
InvestorPlace
Pharma ETFs Gain Post Q1 Earnings
May 09, 2023
Pharma ETFs have been in the green over the past month.
Via
Talk Markets
A Look At Pharma ETFs Post Q4 Earnings
February 08, 2023
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.
Via
Talk Markets
5 Sector ETFs That Beat The Market In December
December 27, 2022
While most segments of the market are suffering from huge losses, a few have performed really well. These are likely to continue outperforming should the trends prevail.
Via
Talk Markets
Pharma ETFs In Focus Post Q3 Earnings
November 09, 2022
Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month.
Via
Talk Markets
Wave of Solid Q3 Earnings Push Pharma ETFs Higher
November 09, 2021
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month.
Via
Talk Markets
Pharma ETFs in Focus Post Q1 Earnings
May 12, 2021
The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail.
Via
Talk Markets
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.